{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:50:05Z","timestamp":1790790605696,"version":"4.1.0"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40263-022-00948-8","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T02:02:30Z","timestamp":1661738550000},"page":"933-949","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["New Oral Drugs for Migraine"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6946-5637","authenticated-orcid":false,"given":"Nazia","family":"Karsan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3260-5904","authenticated-orcid":false,"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"issue":"11","key":"948_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"GBD 2016 Headache Collaborators","year":"2018","unstructured":"GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954\u201376.","journal-title":"Lancet Neurol"},{"key":"948_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0301-0082(00)00010-1","volume":"62","author":"PJ Goadsby","year":"2000","unstructured":"Goadsby PJ. The pharmacology of headache. Prog Neurobiol. 2000;62:509\u201325.","journal-title":"Prog Neurobiol"},{"issue":"5","key":"948_CR3","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1526-4610.2004.04078.x","volume":"44","author":"D Dodick","year":"2004","unstructured":"Dodick D, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44(5):414\u201325.","journal-title":"Headache"},{"issue":"12","key":"948_CR4","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1007\/s12325-020-01494-9","volume":"37","author":"E Leroux","year":"2020","unstructured":"Leroux E, et al. Evaluation of patients with insufficient efficacy and\/or tolerability to triptans for the acute treatment of migraine: a systematic literature review. Adv Ther. 2020;37(12):4765\u201396.","journal-title":"Adv Ther"},{"issue":"6","key":"948_CR5","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478\u201388.","journal-title":"Cephalalgia"},{"issue":"22","key":"948_CR6","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1212\/01.wnl.0000335946.53860.1d","volume":"71","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008;71(22):1821\u20138.","journal-title":"Neurology"},{"issue":"2","key":"948_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/head.14056","volume":"61","author":"TJ Schwedt","year":"2021","unstructured":"Schwedt TJ, et al. Headache characteristics and burden from chronic migraine with medication overuse headache: cross-sectional observations from the Medication Overuse Treatment Strategy trial. Headache. 2021;61(2):351\u201362.","journal-title":"Headache"},{"issue":"5","key":"948_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40263-021-00818-9","volume":"35","author":"C Sun-Edelstein","year":"2021","unstructured":"Sun-Edelstein C, et al. The evolution of medication overuse headache: history, pathophysiology and clinical update. CNS Drugs. 2021;35(5):545\u201365.","journal-title":"CNS Drugs"},{"issue":"2","key":"948_CR9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1526-4610.2007.00868.x","volume":"48","author":"DW Dodick","year":"2008","unstructured":"Dodick DW, et al. Predictors of migraine headache recurrence: a pooled analysis from the eletriptan database. Headache. 2008;48(2):184\u201393.","journal-title":"Headache"},{"issue":"1","key":"948_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s10194-020-01132-3","volume":"21","author":"DB Clemow","year":"2020","unstructured":"Clemow DB, et al. Lasmiditan mechanism of action\u2014review of a selective 5-HT(1F) agonist. J Headache Pain. 2020;21(1):71.","journal-title":"J Headache Pain"},{"issue":"3","key":"948_CR11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00409-9","volume":"21","author":"L Al-Hassany","year":"2022","unstructured":"Al-Hassany L, et al. Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol. 2022;21(3):284\u201394.","journal-title":"Lancet Neurol"},{"key":"948_CR12","doi-asserted-by":"crossref","unstructured":"Bigal ME, et al. Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia. 2014;34(12):968\u201376.","DOI":"10.1177\/0333102414527646"},{"issue":"5","key":"948_CR13","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, et al. Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021;28(5):1716\u201325.","journal-title":"Eur J Neurol"},{"issue":"6","key":"948_CR14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, et al. CGRP as the target of new migraine therapies\u2014successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338\u201350.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"948_CR15","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener HC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804\u201314.","journal-title":"Cephalalgia"},{"issue":"7","key":"948_CR16","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793\u2013803.","journal-title":"Cephalalgia"},{"issue":"6","key":"948_CR17","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","volume":"50","author":"DW Dodick","year":"2010","unstructured":"Dodick DW, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921\u201336.","journal-title":"Headache"},{"issue":"3","key":"948_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/03331024211040467","volume":"42","author":"A Alpuente","year":"2022","unstructured":"Alpuente A, et al. Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks. Cephalalgia. 2022;42(3):186\u201396.","journal-title":"Cephalalgia"},{"issue":"6","key":"948_CR19","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/head.12372","volume":"54","author":"E Cernuda-Moroll\u00f3n","year":"2014","unstructured":"Cernuda-Moroll\u00f3n E, et al. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine. Headache. 2014;54(6):987\u201395.","journal-title":"Headache"},{"key":"948_CR20","first-page":"29","volume":"41","author":"C O'Gorman","year":"2021","unstructured":"O\u2019Gorman C, et al. Efficacy and safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the acute treatment of migraine: results from the MOMENTUM phase 3, randomized, double-blind, active- and placebo-controlled trial. Cephalalgia. 2021;41:29.","journal-title":"Cephalalgia"},{"key":"948_CR21","first-page":"152","volume":"41","author":"A Jones","year":"2021","unstructured":"Jones A, et al. Efficacy and safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the acute treatment of migraine: results from the INTERCEPT phase 3, randomized, double-blind, placebo-controlled Trial. Cephalalgia. 2021;41:152.","journal-title":"Cephalalgia"},{"issue":"Pt 1","key":"948_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/brain\/123.1.9","volume":"123","author":"P Tfelt-Hansen","year":"2000","unstructured":"Tfelt-Hansen P, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain. 2000;123(Pt 1):9\u201318.","journal-title":"Brain"},{"key":"948_CR23","unstructured":"Horton BT, Peters GA, Blumenthal LS. A new product in the treatment of migraine: a preliminary report. In: Proceedings Staff Meeting Mayo Clinic, 1945; 20: 241\u201348."},{"issue":"8","key":"948_CR24","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/head.14184","volume":"61","author":"TR Smith","year":"2021","unstructured":"Smith TR, et al. STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD(\u00ae) ) of dihydroergotamine mesylate, over 24\/52 weeks in acute treatment of migraine attacks in adult patients. Headache. 2021;61(8):1214\u201326.","journal-title":"Headache"},{"issue":"10","key":"948_CR25","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s40261-017-0548-6","volume":"37","author":"A Pal","year":"2017","unstructured":"Pal A, et al. Pharmacokinetics of DFN-15, a novel oral solution of celecoxib, versus celecoxib 400-mg capsules: a randomized crossover study in fasting healthy volunteers. Clin Drug Investig. 2017;37(10):937\u201346.","journal-title":"Clin Drug Investig"},{"key":"948_CR26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2147\/JPR.S287571","volume":"14","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, et al. Acute treatment of migraine with celecoxib oral solution: results of a randomized, placebo-controlled clinical trial. J Pain Res. 2021;14:549\u201360.","journal-title":"J Pain Res"},{"key":"948_CR27","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.2147\/JPR.S322292","volume":"14","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, et al. A multicenter, randomized, double-blind, placebo-controlled study of the efficacy, tolerability, and safety of celecoxib oral solution (ELYXYB) in acute treatment of episodic migraine with or without aura. J Pain Res. 2021;14:2529\u201342.","journal-title":"J Pain Res"},{"issue":"2","key":"948_CR28","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0306-4522(03)00570-0","volume":"122","author":"PJ Goadsby","year":"2003","unstructured":"Goadsby PJ, Classey JD. Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience. 2003;122(2):491\u20138.","journal-title":"Neuroscience"},{"issue":"10","key":"948_CR29","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1046\/j.1468-2982.1999.1910851.x","volume":"19","author":"S Shepheard","year":"1999","unstructured":"Shepheard S, et al. Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia. 1999;19(10):851\u20138.","journal-title":"Cephalalgia"},{"issue":"5","key":"948_CR30","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1097\/j.pain.0000000000001801","volume":"161","author":"A Labastida-Ram\u00edrez","year":"2020","unstructured":"Labastida-Ram\u00edrez A, et al. Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. Pain. 2020;161(5):1092\u20139.","journal-title":"Pain"},{"issue":"1","key":"948_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10194-022-01394-z","volume":"23","author":"JCA Edvinsson","year":"2022","unstructured":"Edvinsson JCA, et al. Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT(1) receptors. J Headache Pain. 2022;23(1):26.","journal-title":"J Headache Pain"},{"issue":"3","key":"948_CR32","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/bph.15699","volume":"179","author":"M Vila-Pueyo","year":"2022","unstructured":"Vila-Pueyo M, et al. The selective 5-HT(1F) receptor agonist lasmiditan inhibits trigeminal nociceptive processing: Implications for migraine and cluster headache. Br J Pharmacol. 2022;179(3):358\u201370.","journal-title":"Br J Pharmacol"},{"issue":"9289","key":"948_CR33","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/S0140-6736(01)06347-4","volume":"358","author":"DJ Goldstein","year":"2001","unstructured":"Goldstein DJ, et al. Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001;358(9289):1230\u20134.","journal-title":"Lancet"},{"key":"948_CR34","first-page":"24","volume":"29","author":"AJ Pilgrim","year":"2009","unstructured":"Pilgrim AJ, et al. COL-144, an orally bioavailable selective 5-HT1F receptor agonist for acute migraine therapy. Cephalalgia. 2009;29:24\u20135.","journal-title":"Cephalalgia"},{"issue":"10","key":"948_CR35","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/0333102410370873","volume":"30","author":"DL Nelson","year":"2010","unstructured":"Nelson DL, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010;30(10):1159\u201369.","journal-title":"Cephalalgia"},{"issue":"10","key":"948_CR36","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1177\/0333102410375512","volume":"30","author":"MD Ferrari","year":"2010","unstructured":"Ferrari MD, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan\u2014a randomised proof-of-concept trial. Cephalalgia. 2010;30(10):1170\u20138.","journal-title":"Cephalalgia"},{"issue":"7","key":"948_CR37","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894\u2013904.","journal-title":"Brain"},{"issue":"24","key":"948_CR38","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","volume":"91","author":"B Kuca","year":"2018","unstructured":"Kuca B, et al. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018;91(24):e2222\u201332.","journal-title":"Neurology"},{"issue":"1","key":"948_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-019-1044-6","volume":"20","author":"RE Shapiro","year":"2019","unstructured":"Shapiro RE, et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain. 2019;20(1):90.","journal-title":"J Headache Pain"},{"issue":"1","key":"948_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0333102419889350","volume":"40","author":"K Knievel","year":"2020","unstructured":"Knievel K, et al. Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans. Cephalalgia. 2020;40(1):19\u201327.","journal-title":"Cephalalgia"},{"issue":"1","key":"948_CR41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/03331024211048507","volume":"42","author":"U Reuter","year":"2022","unstructured":"Reuter U, et al. Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: findings from the CENTURION study. Cephalalgia. 2022;42(1):20\u201330.","journal-title":"Cephalalgia"},{"issue":"2","key":"948_CR42","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s40122-022-00388-8","volume":"11","author":"JH Krege","year":"2022","unstructured":"Krege JH, et al. Lasmiditan for patients with migraine and contraindications to triptans: a post hoc analysis. Pain Ther. 2022;11(2):701\u201312.","journal-title":"Pain Ther"},{"issue":"11","key":"948_CR43","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1177\/0333102419864132","volume":"39","author":"JL Brandes","year":"2019","unstructured":"Brandes JL, et al. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia. 2019;39(11):1343\u201357.","journal-title":"Cephalalgia"},{"issue":"7","key":"948_CR44","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/head.13544","volume":"59","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ, et al. Characterization of dizziness after lasmiditan usage: findings from the SAMURAI and SPARTAN acute migraine treatment randomized trials. Headache. 2019;59(7):1052\u201362.","journal-title":"Headache"},{"issue":"6","key":"948_CR45","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.clinthera.2021.04.004","volume":"43","author":"VT Martin","year":"2021","unstructured":"Martin VT, et al. Tolerability and safety of lasmiditan treatment in elderly patients with migraine: post hoc analyses from randomized studies. Clin Ther. 2021;43(6):1066\u201378.","journal-title":"Clin Ther"},{"issue":"1","key":"948_CR46","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s10194-021-01343-2","volume":"22","author":"C Tassorelli","year":"2021","unstructured":"Tassorelli C, et al. Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine. J Headache Pain. 2021;22(1):132.","journal-title":"J Headache Pain"},{"issue":"5","key":"948_CR47","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1046\/j.1468-2982.1994.1405330.x","volume":"14","author":"MD Ferrari","year":"1994","unstructured":"Ferrari MD, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia. 1994;14(5):330\u20138.","journal-title":"Cephalalgia"},{"issue":"1","key":"948_CR48","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12883-019-1420-5","volume":"19","author":"LS Loo","year":"2019","unstructured":"Loo LS, et al. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN). BMC Neurol. 2019;19(1):191.","journal-title":"BMC Neurol"},{"issue":"3","key":"948_CR49","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/0333102421989232","volume":"41","author":"M Ashina","year":"2021","unstructured":"Ashina M, et al. Randomized, controlled trial of lasmiditan over four migraine attacks: findings from the CENTURION study. Cephalalgia. 2021;41(3):294\u2013304.","journal-title":"Cephalalgia"},{"issue":"3","key":"948_CR50","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1046\/j.1526-4610.1998.3803184.x","volume":"38","author":"V Pfaffenrath","year":"1998","unstructured":"Pfaffenrath V, et al. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache. 1998;38(3):184\u201390.","journal-title":"Headache"},{"issue":"5","key":"948_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2732","volume":"35","author":"EM Pearlman","year":"2020","unstructured":"Pearlman EM, et al. Effects of lasmiditan on simulated driving performance: results of two randomized, blinded, crossover studies with placebo and active controls. Hum Psychopharmacol. 2020;35(5): e2732.","journal-title":"Hum Psychopharmacol"},{"issue":"9","key":"948_CR52","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1093\/brain\/awaa211","volume":"143","author":"C Saengjaroentham","year":"2020","unstructured":"Saengjaroentham C, et al. Differential medication overuse risk of novel anti-migraine therapeutics. Brain. 2020;143(9):2681\u20138.","journal-title":"Brain"},{"key":"948_CR53","doi-asserted-by":"crossref","unstructured":"Orlova YY, Mehla S, Chua AL. Drug safety in episodic migraine management in adults part 1: acute treatments. Curr Pain Headache Rep. 2022.","DOI":"10.1007\/s11916-022-01057-3"},{"key":"948_CR54","doi-asserted-by":"crossref","unstructured":"Woodhead JL, et al. Comparing the liver safety profiles of four next-generation cgrp receptor antagonists to the hepatotoxic CGRP inhibitor telcagepant using quantitative systems toxicology modeling. Toxicol Sci. 2022.","DOI":"10.1093\/toxsci\/kfac051"},{"issue":"3","key":"948_CR55","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1177\/0333102417728873","volume":"39","author":"K Warfvinge","year":"2019","unstructured":"Warfvinge K, Edvinsson L. Distribution of CGRP and CGRP receptor components in the rat brain. Cephalalgia. 2019;39(3):342\u201353.","journal-title":"Cephalalgia"},{"issue":"9","key":"948_CR56","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1177\/0333102420914913","volume":"40","author":"SL Christensen","year":"2020","unstructured":"Christensen SL, et al. No central action of CGRP antagonising drugs in the GTN mouse model of migraine. Cephalalgia. 2020;40(9):924\u201334.","journal-title":"Cephalalgia"},{"issue":"3","key":"948_CR57","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/0333102417736900","volume":"39","author":"L Edvinsson","year":"2019","unstructured":"Edvinsson L, Warfvinge K. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia. 2019;39(3):366\u201373.","journal-title":"Cephalalgia"},{"key":"948_CR58","doi-asserted-by":"publisher","unstructured":"Edvinsson L. Calcitonin gene-related peptide (CGRP) is a key molecule released in acute migraine attacks-successful translation of basic science to clinical practice. J Intern Med. 2022. https:\/\/doi.org\/10.1111\/joim.13506 (Epub ahead of print).","DOI":"10.1111\/joim.13506"},{"issue":"7","key":"948_CR59","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/sj.bjp.0705807","volume":"142","author":"RJ Storer","year":"2004","unstructured":"Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol. 2004;142(7):1171\u201381.","journal-title":"Br J Pharmacol"},{"issue":"9","key":"948_CR60","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1093\/brain\/awq224","volume":"133","author":"O Summ","year":"2010","unstructured":"Summ O, et al. Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain. 2010;133(9):2540\u20138.","journal-title":"Brain"},{"issue":"14","key":"948_CR61","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1177\/0333102415576723","volume":"35","author":"P Pozo-Rosich","year":"2015","unstructured":"Pozo-Rosich P, et al. Periaqueductal gray calcitonin gene-related peptide modulates trigeminovascular neurons. Cephalalgia. 2015;35(14):1298\u2013307.","journal-title":"Cephalalgia"},{"issue":"24","key":"948_CR62","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1007\/BF01466734","volume":"52","author":"K Felgenhauer","year":"1974","unstructured":"Felgenhauer K. Protein size and cerebrospinal fluid composition. Klin Wochenschr. 1974;52(24):1158\u201364.","journal-title":"Klin Wochenschr"},{"key":"948_CR63","doi-asserted-by":"publisher","first-page":"10664","DOI":"10.1021\/jm3013147","volume":"55","author":"G Luo","year":"2012","unstructured":"Luo G, et al. Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyri din-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine. J Med Chem. 2012;55:10664\u201310651.","journal-title":"J Med Chem"},{"key":"948_CR64","doi-asserted-by":"crossref","unstructured":"Moore E, et al. Characterization of ubrogepant: a potent and selective antagonist of the human calcitonin gene\u2012related peptide receptor. J Pharmacol Exp Ther. 2020.","DOI":"10.1124\/jpet.119.261065"},{"issue":"23","key":"948_CR65","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230\u201341.","journal-title":"N Engl J Med"},{"issue":"19","key":"948_CR66","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887\u201398.","journal-title":"JAMA"},{"issue":"3","key":"948_CR67","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/head.14089","volume":"61","author":"AM Blumenfeld","year":"2021","unstructured":"Blumenfeld AM, et al. Efficacy of ubrogepant based on prior exposure and response to triptans: a post hoc analysis. Headache. 2021;61(3):422\u20139.","journal-title":"Headache"},{"issue":"1","key":"948_CR68","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s10194-022-01419-7","volume":"23","author":"RB Lipton","year":"2022","unstructured":"Lipton RB, et al. Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials. J Headache Pain. 2022;23(1):50.","journal-title":"J Headache Pain"},{"issue":"1","key":"948_CR69","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40120-021-00234-7","volume":"10","author":"S Hutchinson","year":"2021","unstructured":"Hutchinson S, et al. Ubrogepant for the acute treatment of migraine: pooled efficacy, safety, and tolerability from the ACHIEVE I and ACHIEVE II phase 3 randomized trials. Neurol Ther. 2021;10(1):235\u201349.","journal-title":"Neurol Ther"},{"issue":"9","key":"948_CR70","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/03331024211000311","volume":"41","author":"S Hutchinson","year":"2021","unstructured":"Hutchinson S, et al. Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II. Cephalalgia. 2021;41(9):979\u201390.","journal-title":"Cephalalgia"},{"issue":"5","key":"948_CR71","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1177\/0333102420970523","volume":"41","author":"PJ Goadsby","year":"2021","unstructured":"Goadsby PJ, et al. Time course of efficacy of ubrogepant for the acute treatment of migraine: clinical implications. Cephalalgia. 2021;41(5):546\u201360.","journal-title":"Cephalalgia"},{"issue":"1","key":"948_CR72","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s12325-021-01923-3","volume":"39","author":"AM Blumenfeld","year":"2022","unstructured":"Blumenfeld AM, et al. Ubrogepant is safe and efficacious in participants taking concomitant preventive medication for migraine: a pooled analysis of phase 3 trials. Adv Ther. 2022;39(1):692\u2013705.","journal-title":"Adv Ther"},{"issue":"4","key":"948_CR73","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/head.14062","volume":"61","author":"CC Chiang","year":"2021","unstructured":"Chiang CC, et al. Real-world efficacy, tolerability, and safety of ubrogepant. Headache. 2021;61(4):620\u20137.","journal-title":"Headache"},{"issue":"10200","key":"948_CR74","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737\u201345.","journal-title":"Lancet"},{"issue":"2","key":"948_CR75","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142\u20139.","journal-title":"N Engl J Med"},{"key":"948_CR76","first-page":"18","volume":"38","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, et al. Rimegepant 75 mg, an oral calcitonin gene-related peptide antagonist, for the acute treatment of migraine: two phase 3, double-blind, randomized, placebo-controlled trials. Cephalalgia. 2018;38:18\u20139.","journal-title":"Cephalalgia"},{"issue":"2","key":"948_CR77","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0333102413500727","volume":"34","author":"R Marcus","year":"2014","unstructured":"Marcus R, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34(2):114\u201325.","journal-title":"Cephalalgia"},{"issue":"10268","key":"948_CR78","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, et al. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51\u201360.","journal-title":"Lancet"},{"issue":"20","key":"948_CR79","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1212\/WNL.0b013e3182377dbb","volume":"77","author":"AJ Nagy","year":"2011","unstructured":"Nagy AJ, et al. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011;77(20):1827\u201332.","journal-title":"Neurology"},{"key":"948_CR80","unstructured":"https:\/\/www.nice.org.uk\/guidance\/TA682. Erenumab for preventing migraine 2021. Accessed 24 May 2022."},{"issue":"23","key":"948_CR81","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1001\/jama.2021.7665","volume":"325","author":"PK Winner","year":"2021","unstructured":"Winner PK, et al. Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA. 2021;325(23):2348\u201356.","journal-title":"JAMA"},{"issue":"3","key":"948_CR82","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241\u201354.","journal-title":"Cephalalgia"},{"issue":"13","key":"948_CR83","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365\u201377.","journal-title":"Neurology"},{"key":"948_CR84","doi-asserted-by":"crossref","unstructured":"Hutchinson S, et al. Oral rimegepant 75 mg is safe and well tolerated in adults with migraine and cardiovascular risk factors: results of a multicenter, long-term, open-label safety study. Neurology 96 (S15):1995.","DOI":"10.1212\/WNL.96.15_supplement.1995"},{"issue":"1","key":"948_CR85","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-021-01378-5","volume":"23","author":"K Johnston","year":"2022","unstructured":"Johnston K, et al. Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant\u2014post hoc results from an open label safety study (BHV3000-201). J Headache Pain. 2022;23(1):10.","journal-title":"J Headache Pain"},{"issue":"9","key":"948_CR86","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","volume":"19","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial. Lancet Neurol. 2020;19(9):727\u201337.","journal-title":"Lancet Neurol"},{"issue":"8","key":"948_CR87","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695\u2013706.","journal-title":"N Engl J Med"},{"issue":"1","key":"948_CR88","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/03331024211042385","volume":"42","author":"TJ Schwedt","year":"2022","unstructured":"Schwedt TJ, et al. Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial. Cephalalgia. 2022;42(1):3\u201311.","journal-title":"Cephalalgia"},{"issue":"4","key":"948_CR89","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2217\/pmt-2021-0073","volume":"12","author":"R Boinpally","year":"2022","unstructured":"Boinpally R, et al. Atogepant and sumatriptan: no clinically relevant drug-drug interactions in a randomized, open-label, crossover trial. Pain Manag. 2022;12(4):499\u2013508.","journal-title":"Pain Manag"},{"key":"948_CR90","doi-asserted-by":"crossref","unstructured":"Pozo-Roisch P, et al. Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial. Headache, 2022. (in press).","DOI":"10.1212\/WNL.0000000000203657"},{"key":"948_CR91","first-page":"104","volume":"61","author":"R Croop","year":"2021","unstructured":"Croop R, et al. Intranasal zavegepant is effective and well tolerated for the acute treatment of migraine: a phase 2\/3 dose-ranging clinical trial. Headache. 2021;61:104\u20135.","journal-title":"Headache"},{"key":"948_CR92","unstructured":"Biohaven achieves positive topline results in pivotal phase 2\/3 study of vazegepant, the first and only intranasal CGRP receptor antagonist in clinical development for the acute treatment of migraine [press release]. 2019, Biohaven Pharmaceuticals; biohavenpharma.com\/investors\/news-events\/press-releases\/12-17-2019: New Haven, CT."},{"key":"948_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127624","volume":"31","author":"SE Mercer","year":"2021","unstructured":"Mercer SE, et al. Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists. Bioorg Med Chem Lett. 2021;31: 127624.","journal-title":"Bioorg Med Chem Lett"},{"issue":"2\u20133","key":"948_CR94","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF03033787","volume":"2","author":"W Danysz","year":"2000","unstructured":"Danysz W, et al. Neuroprotective and symptomatological action of memantine relevant for Alzheimer\u2019s disease\u2014a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res. 2000;2(2\u20133):85\u201397.","journal-title":"Neurotox Res"},{"issue":"2","key":"948_CR95","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s13311-018-0616-5","volume":"15","author":"J Hoffmann","year":"2018","unstructured":"Hoffmann J, Charles A. Glutamate and its receptors as therapeutic targets for migraine. Neurotherapeutics. 2018;15(2):361\u201370.","journal-title":"Neurotherapeutics"},{"issue":"3","key":"948_CR96","doi-asserted-by":"publisher","first-page":"286","DOI":"10.4103\/aian.AIAN_294_18","volume":"22","author":"S Shanmugam","year":"2019","unstructured":"Shanmugam S, et al. Memantine ameliorates migraine headache. Ann Indian Acad Neurol. 2019;22(3):286\u201390.","journal-title":"Ann Indian Acad Neurol"},{"issue":"3","key":"948_CR97","first-page":"1","volume":"3","author":"D Kashipaza","year":"2018","unstructured":"Kashipaza D, Emadi S. The effect of memantine on prophylaxis of chronic migraine headache. ARC Journal of Neuroscience. 2018;3(3):1\u20137.","journal-title":"ARC Journal of Neuroscience"},{"issue":"1","key":"948_CR98","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/head.12732","volume":"56","author":"R Noruzzadeh","year":"2016","unstructured":"Noruzzadeh R, et al. Memantine for prophylactic treatment of migraine without aura: a randomized double-blind placebo-controlled study. Headache. 2016;56(1):95\u2013103.","journal-title":"Headache"},{"issue":"3","key":"948_CR99","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/WNF.0000000000000504","volume":"45","author":"T Zhou","year":"2022","unstructured":"Zhou T, Tang Y, Zhu H. Effectiveness and safety of memantine for headache: a meta-analysis of randomized controlled studies. Clin Neuropharmacol. 2022;45(3):40\u20134.","journal-title":"Clin Neuropharmacol"},{"key":"948_CR100","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1111\/bph.14116","volume":"175","author":"N Zisapel","year":"2018","unstructured":"Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol. 2018;175(16):3190\u20139.","journal-title":"Br J Pharmacol"},{"issue":"10","key":"948_CR101","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1177\/0333102414542662","volume":"34","author":"AD Nesbitt","year":"2014","unstructured":"Nesbitt AD, Leschziner GD, Peatfield RC. Headache, drugs and sleep. Cephalalgia. 2014;34(10):756\u201366.","journal-title":"Cephalalgia"},{"issue":"4\u20135","key":"948_CR102","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/03331024211046618","volume":"42","author":"R Messina","year":"2022","unstructured":"Messina R, et al. Clinical correlates of hypothalamic functional changes in migraine patients. Cephalalgia. 2022;42(4\u20135):279\u201390.","journal-title":"Cephalalgia"},{"issue":"3","key":"948_CR103","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/j.1600-079X.2011.00895.x","volume":"51","author":"M Wilhelmsen","year":"2011","unstructured":"Wilhelmsen M, et al. Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res. 2011;51(3):270\u20137.","journal-title":"J Pineal Res"},{"issue":"7","key":"948_CR104","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/head.13828","volume":"60","author":"I Liampas","year":"2020","unstructured":"Liampas I, et al. Endogenous melatonin levels and therapeutic use of exogenous melatonin in migraine: systematic review and meta-analysis. Headache. 2020;60(7):1273\u201399.","journal-title":"Headache"},{"issue":"2","key":"948_CR105","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12663","volume":"69","author":"PT Tseng","year":"2020","unstructured":"Tseng PT, et al. The association between melatonin and episodic migraine: a pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy. J Pineal Res. 2020;69(2): e12663.","journal-title":"J Pineal Res"},{"issue":"4","key":"948_CR106","first-page":"385","volume":"35","author":"M Ebrahimi-Monfared","year":"2017","unstructured":"Ebrahimi-Monfared M, et al. Use of melatonin versus valproic acid in prophylaxis of migraine patients: A double-blind randomized clinical trial. Restor Neurol Neurosci. 2017;35(4):385\u201393.","journal-title":"Restor Neurol Neurosci"},{"issue":"10","key":"948_CR107","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1136\/jnnp-2016-313458","volume":"87","author":"AL Goncalves","year":"2016","unstructured":"Goncalves AL, et al. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry. 2016;87(10):1127\u201332.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"948_CR108","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2174\/1574886309666140605114614","volume":"10","author":"R Fallah","year":"2015","unstructured":"Fallah R, Shoroki FF, Ferdosian F. Safety and efficacy of melatonin in pediatric migraine prophylaxis. Curr Drug Saf. 2015;10(2):132\u20135.","journal-title":"Curr Drug Saf"},{"issue":"17","key":"948_CR109","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1212\/WNL.0b013e3181f9618c","volume":"75","author":"KB Alstadhaug","year":"2010","unstructured":"Alstadhaug KB, et al. Prophylaxis of migraine with melatonin: a randomized controlled trial. Neurology. 2010;75(17):1527\u201332.","journal-title":"Neurology"},{"issue":"1","key":"948_CR110","first-page":"47","volume":"12","author":"R Fallah","year":"2018","unstructured":"Fallah R, Fazelishoroki F, Sekhavat L. A randomized clinical trial comparing the efficacy of melatonin and amitriptyline in migraine prophylaxis of children. Iran J Child Neurol. 2018;12(1):47\u201354.","journal-title":"Iran J Child Neurol"},{"issue":"4","key":"948_CR111","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10072-008-0983-5","volume":"29","author":"S Miano","year":"2008","unstructured":"Miano S, et al. Melatonin to prevent migraine or tension-type headache in children. Neurol Sci. 2008;29(4):285\u20137.","journal-title":"Neurol Sci"},{"issue":"8","key":"948_CR112","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1111\/head.13934","volume":"60","author":"AA Gelfand","year":"2020","unstructured":"Gelfand AA, et al. Melatonin for acute treatment of migraine in children and adolescents: a pilot randomized trial. Headache. 2020;60(8):1712\u201321.","journal-title":"Headache"},{"issue":"6","key":"948_CR113","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/j.1526-4610.2007.00842.x","volume":"47","author":"P Holland","year":"2007","unstructured":"Holland P, Goadsby PJ. The hypothalamic orexinergic system: pain and primary headaches. Headache. 2007;47(6):951\u201362.","journal-title":"Headache"},{"issue":"10","key":"948_CR114","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0333102414541687","volume":"34","author":"PR Holland","year":"2014","unstructured":"Holland PR. Headache and sleep: shared pathophysiological mechanisms. Cephalalgia. 2014;34(10):725\u201344.","journal-title":"Cephalalgia"},{"issue":"1","key":"948_CR115","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1046\/j.1468-2982.2003.00343.x","volume":"23","author":"N Dahmen","year":"2003","unstructured":"Dahmen N, et al. Increased frequency of migraine in narcoleptic patients: a confirmatory study. Cephalalgia. 2003;23(1):14\u20139.","journal-title":"Cephalalgia"},{"issue":"3","key":"948_CR116","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.pain.2004.02.005","volume":"109","author":"T Bartsch","year":"2004","unstructured":"Bartsch T, et al. Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain. 2004;109(3):367\u201378.","journal-title":"Pain"},{"issue":"10","key":"948_CR117","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1111\/j.1460-9568.2006.05168.x","volume":"24","author":"PR Holland","year":"2006","unstructured":"Holland PR, Akerman S, Goadsby PJ. Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci. 2006;24(10):2825\u201333.","journal-title":"Eur J Neurosci"},{"key":"948_CR118","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.nbd.2014.10.022","volume":"74","author":"J Hoffmann","year":"2015","unstructured":"Hoffmann J, et al. Evidence for orexinergic mechanisms in migraine. Neurobiol Dis. 2015;74:137\u201343.","journal-title":"Neurobiol Dis"},{"issue":"7","key":"948_CR119","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/j.1468-2982.2008.01566.x","volume":"28","author":"P Sarchielli","year":"2008","unstructured":"Sarchielli P, et al. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid. Cephalalgia. 2008;28(7):714\u201322.","journal-title":"Cephalalgia"},{"issue":"5","key":"948_CR120","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1177\/0333102414544979","volume":"35","author":"A Chabi","year":"2015","unstructured":"Chabi A, et al. Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia. 2015;35(5):379\u201388.","journal-title":"Cephalalgia"},{"issue":"4","key":"948_CR121","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/86075","volume":"4","author":"G Bhave","year":"2001","unstructured":"Bhave G, et al. Peripheral group I metabotropic glutamate receptors modulate nociception in mice. Nat Neurosci. 2001;4(4):417\u201323.","journal-title":"Nat Neurosci"},{"issue":"8","key":"948_CR122","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/acn3.302","volume":"3","author":"MW Waung","year":"2016","unstructured":"Waung MW, et al. Metabotropic glutamate receptor 5: a target for migraine therapy. Ann Clin Transl Neurol. 2016;3(8):560\u201371.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"948_CR123","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s10194-020-01206-2","volume":"21","author":"Y Niu","year":"2020","unstructured":"Niu Y, et al. Metabotropic glutamate receptor 5 regulates synaptic plasticity in a chronic migraine rat model through the PKC\/NR2B signal. J Headache Pain. 2020;21(1):139.","journal-title":"J Headache Pain"},{"issue":"9","key":"948_CR124","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.parkreldis.2014.05.003","volume":"20","author":"O Rascol","year":"2014","unstructured":"Rascol O, et al. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat Disord. 2014;20(9):947\u201356.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"948_CR125","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/sj.bjp.0704842","volume":"137","author":"S Akerman","year":"2002","unstructured":"Akerman S, et al. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol. 2002;137(1):62\u20138.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"948_CR126","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/0333102412466967","volume":"33","author":"DK Bhatt","year":"2013","unstructured":"Bhatt DK, et al. NXN-188, a selective nNOS inhibitor and a 5-HT1B\/1D receptor agonist, inhibits CGRP release in preclinical migraine models. Cephalalgia. 2013;33(2):87\u2013100.","journal-title":"Cephalalgia"},{"issue":"3","key":"948_CR127","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ana.21897","volume":"67","author":"M De Felice","year":"2010","unstructured":"De Felice M, et al. Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol. 2010;67(3):325\u201337.","journal-title":"Ann Neurol"},{"key":"948_CR128","first-page":"38","volume":"11","author":"RA Medve","year":"2010","unstructured":"Medve RA, Lategan TW. A phase 2 multicenter, randomized, double-blind, parallel-group, placebo-controlled study of NXN-188 dihydrochloride in acute migraine without aura. J Headache Pain. 2010;11:38.","journal-title":"J Headache Pain"},{"issue":"2","key":"948_CR129","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s13311-018-0619-2","volume":"15","author":"N Karsan","year":"2018","unstructured":"Karsan N, Gonzales EB, Dussor G. Targeted acid-sensing ion channel therapies for migraine. Neurotherapeutics. 2018;15(2):402\u201314.","journal-title":"Neurotherapeutics"},{"issue":"4","key":"948_CR130","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/ana.23653","volume":"72","author":"PR Holland","year":"2012","unstructured":"Holland PR, et al. Acid-sensing ion channel 1: a novel therapeutic target for migraine with aura. Ann Neurol. 2012;72(4):559\u201363.","journal-title":"Ann Neurol"},{"issue":"6","key":"948_CR131","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.molcel.2015.04.018","volume":"58","author":"JM Booe","year":"2015","unstructured":"Booe JM, et al. Structural basis for receptor activity-modifying protein-dependent selective peptide recognition by a G protein-coupled receptor. Mol Cell. 2015;58(6):1040\u201352.","journal-title":"Mol Cell"},{"key":"948_CR132","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1100\/tsw.2001.23","volume":"1","author":"L Edvinsson","year":"2001","unstructured":"Edvinsson L, Goadsby PJ, Uddman R. Amylin: localization, effects on cerebral arteries and on local cerebral blood flow in the cat. Sci World J. 2001;1:168\u201380.","journal-title":"Sci World J"},{"issue":"6","key":"948_CR133","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s12031-020-01493-z","volume":"70","author":"L Edvinsson","year":"2020","unstructured":"Edvinsson L, Grell AS, Warfvinge K. Expression of the CGRP Family of neuropeptides and their receptors in the trigeminal ganglion. J Mol Neurosci. 2020;70(6):930\u201344.","journal-title":"J Mol Neurosci"},{"issue":"5","key":"948_CR134","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0149-7634(96)00023-1","volume":"21","author":"D van Rossum","year":"1997","unstructured":"van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev. 1997;21(5):649\u201378.","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"948_CR135","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/0333102420977106","volume":"41","author":"P Irimia","year":"2021","unstructured":"Irimia P, et al. Interictal amylin levels in chronic migraine patients: a case-control study. Cephalalgia. 2021;41(5):604\u201312.","journal-title":"Cephalalgia"},{"issue":"10","key":"948_CR136","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.clinthera.2005.10.009","volume":"27","author":"GJ Ryan","year":"2005","unstructured":"Ryan GJ, Jobe LJ, Martin R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther. 2005;27(10):1500\u201312.","journal-title":"Clin Ther"},{"issue":"6","key":"948_CR137","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/ana.26072","volume":"89","author":"H Ghanizada","year":"2021","unstructured":"Ghanizada H, et al. Amylin analog pramlintide induces migraine-like attacks in patients. Ann Neurol. 2021;89(6):1157\u201371.","journal-title":"Ann Neurol"},{"key":"948_CR138","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.lfs.2017.11.029","volume":"192","author":"A Mendiguren","year":"2018","unstructured":"Mendiguren A, Aostri E, Pineda J. Regulation of noradrenergic and serotonergic systems by cannabinoids: relevance to cannabinoid-induced effects. Life Sci. 2018;192:115\u201327.","journal-title":"Life Sci"},{"issue":"3","key":"948_CR139","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/head.14267","volume":"62","author":"R Greco","year":"2022","unstructured":"Greco R, et al. The endocannabinoid system and related lipids as potential targets for the treatment of migraine-related pain. Headache. 2022;62(3):227\u201340.","journal-title":"Headache"},{"issue":"5","key":"948_CR140","doi-asserted-by":"publisher","first-page":"705","DOI":"10.33549\/physiolres.934159","volume":"68","author":"M Zubrzycki","year":"2019","unstructured":"Zubrzycki M, Stasiolek M, Zubrzycka M. Opioid and endocannabinoid system in orofacial pain. Physiol Res. 2019;68(5):705\u201315.","journal-title":"Physiol Res"},{"issue":"2","key":"948_CR141","first-page":"192","volume":"29","author":"EB Russo","year":"2008","unstructured":"Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 2008;29(2):192\u2013200.","journal-title":"Neuro Endocrinol Lett"},{"issue":"8","key":"948_CR142","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1097\/j.pain.0000000000002214","volume":"162","author":"T Yamamoto","year":"2021","unstructured":"Yamamoto T, et al. Selective targeting of peripheral cannabinoid receptors prevents behavioral symptoms and sensitization of trigeminal neurons in mouse models of migraine and medication overuse headache. Pain. 2021;162(8):2246\u201362.","journal-title":"Pain"},{"issue":"Suppl 2","key":"948_CR143","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/head.13585","volume":"59 Suppl 2","author":"Z Bertels","year":"2019","unstructured":"Bertels Z, Pradhan AAA. Emerging Treatment Targets for Migraine and Other Headaches. Headache. 2019;59 Suppl 2(Suppl 2):50\u201365.","journal-title":"Headache"},{"issue":"3","key":"948_CR144","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/WCO.0000000000000311","volume":"29","author":"A Charles","year":"2016","unstructured":"Charles A, Pradhan AA. Delta-opioid receptors as targets for migraine therapy. Curr Opin Neurol. 2016;29(3):314\u20139.","journal-title":"Curr Opin Neurol"},{"key":"948_CR145","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.neuropharm.2018.12.017","volume":"148","author":"LS Moye","year":"2019","unstructured":"Moye LS, et al. Delta opioid receptor agonists are effective for multiple types of headache disorders. Neuropharmacology. 2019;148:77\u201386.","journal-title":"Neuropharmacology"},{"issue":"8","key":"948_CR146","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1177\/0333102417702120","volume":"37","author":"JY Xie","year":"2017","unstructured":"Xie JY, et al. Kappa opioid receptor antagonists: a possible new class of therapeutics for migraine prevention. Cephalalgia. 2017;37(8):780\u201394.","journal-title":"Cephalalgia"},{"issue":"1","key":"948_CR147","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/0333102418777507","volume":"39","author":"LS Moye","year":"2019","unstructured":"Moye LS, et al. The development of a mouse model of mTBI-induced post-traumatic migraine, and identification of the delta opioid receptor as a novel therapeutic target. Cephalalgia. 2019;39(1):77\u201390.","journal-title":"Cephalalgia"},{"issue":"9","key":"948_CR148","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1111\/bph.12591","volume":"171","author":"AA Pradhan","year":"2014","unstructured":"Pradhan AA, et al. \u03b4-Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice. Br J Pharmacol. 2014;171(9):2375\u201384.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"948_CR149","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00213-015-4195-4","volume":"233","author":"EM Richards","year":"2016","unstructured":"Richards EM, et al. A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression. Psychopharmacology. 2016;233(6):1119\u201330.","journal-title":"Psychopharmacology"},{"issue":"1\u20132","key":"948_CR150","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0304-3959(02)00259-2","volume":"101","author":"JC Eisenach","year":"2003","unstructured":"Eisenach JC, Carpenter R, Curry R. Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis. Pain. 2003;101(1\u20132):89\u201395.","journal-title":"Pain"},{"issue":"12","key":"948_CR151","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1177\/0333102419859313","volume":"39","author":"EG Doty","year":"2019","unstructured":"Doty EG, et al. Sustained responses to lasmiditan: results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine. Cephalalgia. 2019;39(12):1569\u201376.","journal-title":"Cephalalgia"},{"issue":"1","key":"948_CR152","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-019-1032-x","volume":"20","author":"LS Loo","year":"2019","unstructured":"Loo LS, et al. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. J Headache Pain. 2019;20(1):84.","journal-title":"J Headache Pain"},{"issue":"10","key":"948_CR153","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/head.13636","volume":"59","author":"M Ashina","year":"2019","unstructured":"Ashina M, et al. Onset of efficacy following oral treatment with lasmiditan for the acute treatment of migraine: integrated results from 2 randomized double-blind placebo-controlled phase 3 clinical studies. Headache. 2019;59(10):1788\u2013801.","journal-title":"Headache"},{"issue":"2","key":"948_CR154","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40120-020-00185-5","volume":"9","author":"T Smith","year":"2020","unstructured":"Smith T, et al. Improvement in function after lasmiditan treatment: post hoc analysis of data from phase 3 studies. Neurol Ther. 2020;9(2):459\u201371.","journal-title":"Neurol Ther"},{"issue":"8","key":"948_CR155","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/head.13897","volume":"60","author":"SJ Tepper","year":"2020","unstructured":"Tepper SJ, et al. Evaluation of 2-hour post-dose efficacy of lasmiditan for the acute treatment of difficult-to-treat migraine attacks. Headache. 2020;60(8):1601\u201315.","journal-title":"Headache"},{"issue":"1","key":"948_CR156","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10194-021-01303-w","volume":"22","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, et al. A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN. J Headache Pain. 2021;22(1):101.","journal-title":"J Headache Pain"},{"issue":"5","key":"948_CR157","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/head.14122","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, et al. Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients. Headache. 2021;61(5):755\u201365.","journal-title":"Headache"},{"issue":"1","key":"948_CR158","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/head.13682","volume":"60","author":"J Ailani","year":"2020","unstructured":"Ailani J, et al. Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache. 2020;60(1):141\u201352.","journal-title":"Headache"},{"issue":"4","key":"948_CR159","first-page":"686","volume":"60","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, et al. Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials. ACHIEVE I and II Headache. 2020;60(4):686\u2013700.","journal-title":"ACHIEVE I and II. Headache"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00948-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00948-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00948-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T18:46:37Z","timestamp":1727894797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00948-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":159,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["948"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00948-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,29]]},"assertion":[{"value":"10 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No specific funding was granted for the preparation and publication of this manuscript.\u00a0Open access was funded by\u00a0King\u2019s College London.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"NK has no relevant financial disclosures to report. PJG reports, over the last 36 months, grants and personal fees from Eli-Lilly and Company; a grant from Celgene; personal fees from Aeon Biopharma, Allergan\/Abbvie, Biohaven Pharmaceuticals Inc., CoolTech LLC, Dr Reddys, Epalex, Impel Neuropharma, Lundbeck, Novartis, Praxis, Sanofi, Satsuma and Teva Pharmaceuticals; personal fees for advice through Gerson Lehrman Group, Guidepoint, SAI Med Partners, Vector Metric; fees for educational materials from CME Outfitters, Omnia Education, WebMD; publishing royalties or fees from Massachusetts Medical Society, Oxford University Press, UptoDate and Wolters Kluwer; and for medicolegal advice in headache: and a patent magnetic stimulation for headache (No. WO2016090333 A1) assigned to eNeura without fee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests\/Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"NK reviewed the literature and was responsible for drafting the manuscript, including producing the tables. PJG provided expert review and proofread the manuscript prior to submission for publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}